Aroda Vanita R, Ratner Robert
Med Star Clinical Research Center, 650 Pennsylvania Avenue SE, Washington, DC 20003, USA.
J Clin Endocrinol Metab. 2008 Sep;93(9):3259-65. doi: 10.1210/jc.2008-1091.
Prediabetes consists of impaired fasting glucose and/or impaired glucose tolerance and is a significant risk factor for the development of type 2 diabetes, microvascular, and macrovascular disease. The values used to define prediabetes are arbitrary, because prediabetes represents an intermediary category along the continuum from normal glucose levels and tolerance to overt hyperglycemia. The progression from prediabetes to type 2 diabetes occurs over many years, strong evidence to support intervention to delay the progression from prediabetes to diabetes. Large, randomized prospective studies with lifestyle intervention and/or various modes of pharmacotherapy have demonstrated successful delay of diabetes. Several issues in the management of prediabetes remain controversial, such as the role of pharmacotherapy and when to escalate treatment. This article will review some of the issues surrounding the identification and treatment of prediabetes, with an interpretation of the available data to help guide management.
糖尿病前期包括空腹血糖受损和/或糖耐量受损,是2型糖尿病、微血管和大血管疾病发生的重要危险因素。用于定义糖尿病前期的值是任意的,因为糖尿病前期代表了从正常血糖水平和耐糖能力到明显高血糖这一连续过程中的一个中间类别。从糖尿病前期进展到2型糖尿病需要多年时间,有强有力的证据支持进行干预以延缓从糖尿病前期进展到糖尿病。采用生活方式干预和/或各种药物治疗方式的大型随机前瞻性研究已证明成功延缓了糖尿病的发生。糖尿病前期管理中的几个问题仍存在争议,如药物治疗的作用以及何时加强治疗。本文将回顾围绕糖尿病前期识别和治疗的一些问题,并对现有数据进行解读以帮助指导管理。